Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

8.6%

3 terminated/withdrawn out of 35 trials

Success Rate

70.0%

-16.5% vs industry average

Late-Stage Pipeline

29%

10 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

12(35.3%)

Phase 1

10(29.4%)

Phase 3

8(23.5%)

N/A

2(5.9%)

Phase 4

2(5.9%)

34Total

Phase 2(12)

Phase 1(10)

Phase 3(8)

N/A(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (35)

Showing 20 of 35 trials

NCT07413536Phase 1Not Yet Recruiting

A Phase Ia Single Ascending-Dose Study of Subcutaneous EB070 Injection in Healthy Volunteers

Role: lead

NCT07354984Phase 2Not Yet Recruiting

A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Role: collaborator

NCT06879691Phase 4Active Not Recruiting

A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma

Role: lead

NCT05278728Phase 1Completed

Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer

Role: lead

NCT06781073Phase 3Completed

Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma

Role: lead

NCT06633055Phase 1Not Yet Recruiting

A Phase I Clinical Trial of JH013 Injection

Role: lead

NCT05978050Phase 3Recruiting

Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma

Role: lead

NCT06422156Phase 2Not Yet Recruiting

SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer

Role: collaborator

NCT02395016Phase 3Completed

A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer

Role: lead

NCT06343116Phase 3Not Yet Recruiting

Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer

Role: lead

NCT06333821Phase 3Not Yet Recruiting

A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

Role: lead

NCT05986162Phase 1Unknown

Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis

Role: lead

NCT05978544Phase 1Unknown

Safety and Preliminary Clinical Activity of Itolizumab in ARDS

Role: lead

NCT04949503Completed

A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN

Role: lead

NCT04532229Phase 3Unknown

Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children

Role: lead

NCT05823675Phase 1Unknown

Safety and Clinical Activity of Itolizumab in aGVHD

Role: lead

NCT02649270Phase 1Terminated

Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Psoriasis

Role: lead

NCT02591784Phase 2Completed

Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer

Role: lead

NCT04882462Phase 2Unknown

Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.

Role: collaborator

NCT03388372Phase 2Completed

Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma

Role: lead